Proteasome Inhibitor MG-132 and PKC-ι-Specific Inhibitor ICA-1S Degrade Mutant p53 and Induce Apoptosis in Ovarian...

Area of Science:

• Gynecologic Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Ovarian cancer has a poor prognosis, with a 5-year survival rate around 50%.
• Key molecular alterations in ovarian cancer include p53 gene mutations and atypical protein kinase C iota (PKC-ι) overexpression.
• Targeting these specific pathways presents a therapeutic opportunity.

Purpose of the Study:

• To investigate the therapeutic potential of a PKC-ι inhibitor (ICA-1S) and a proteasome inhibitor (MG-132) in ovarian cancer.
• To elucidate the effects of these agents on cell proliferation, p53 levels, and cell death pathways.
• To evaluate combination therapy for ovarian cancer treatment.

Main Methods:

• Cell proliferation and cytotoxicity assays were performed.
• Western blotting, immunofluorescence, and flow cytometry were used to analyze protein levels and cellular processes.
• Small interfering RNA (siRNA) and co-immunoprecipitation were employed to study molecular interactions.
• Experiments were conducted on established ovarian cancer cell lines.

Main Results:

• Both ICA-1S and MG-132 significantly inhibited ovarian cancer cell proliferation.
• ICA-1S effectively reduced the levels of oncogenic PKC-ι.
• Both agents decreased mutated p53 levels in ES-2 cells via distinct mechanisms.
• MG-132 increased wild-type p53 by inhibiting proteasomal degradation in HEY-T30 cells.
• MG-132 induced apoptosis and autophagy in ovarian cancer cell lines.

Conclusions:

• ICA-1S demonstrates efficacy in reducing oncogenic PKC-ι, a key factor in ovarian cancer.
• Combined treatment with ICA-1S and MG-132 shows promise for targeting both mutated p53 and PKC-ι.
• These findings suggest potential therapeutic strategies for specific ovarian cancer subtypes.